The FDA-approved anti-EGFR monoclonal antibody cetuximab (Cet) is used as first-line therapy, in combination with chemotherapy, for metastatic, KRAS wild-type CRC [21,22]. This evidence concerns the gene EGFR and colorectal carcinoma.